Shots:
In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology
PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology
For…
Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EC, and China’s NMPA. This month’s report includes 13 small molecules, 7 devices, 3 biologics ADC, 3 gene therapy, 1 antineoplastics, 1 protein, 1 peptide, 1 recombinant enzyme & 1 vaccine
NRx Pharmaceuticals’ NRX-101 small molecule, focused…
Shots:
2023 remained a year of notable approvals by the US FDA. Around 55 drugs were approved, by the US FDA in 2023
PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Neurology, and Hematology
For the complete report with analysis, reach out to us…
Shots:
In the next installment of Dealmaker 2023, we bring an informative report on the Top M&A based on the Deal Value
The report revolves around Pfizer, which signed 16 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases that have summed to a total of $63.23B
Propelled by the invaluable…
Shots:
As the year began, PharmaShots was busy analyzing the deals throughout 2023 to prepare a special report, viz. JP Morgan 2024 Special: Deal Maker of the Year 2023 (Part 01)
The report features Roche, that signed 26 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases
Propelled by the invaluable…
2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.
Top 20 Radiopharma Companies Based on Market Cap
Shots:
Integrating scintigraphy with…
Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EMA and China. This month’s report includes 3 biological drugs, 12 small molecules, 13 cell and gene therapies, 1 peptide, 3 exosome-based therapy and 4 devices
Atsena Therapeutics’ capsid AAV.SPR gene therapy, focused on the treatment of Leber congenital…
The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most renowned pharmaceutical manufacturing shows in Singapore for pharmaceutical and biomanufacturing professionals. The annual event highlights the best practices and services from manufacturing facility design to finished products.
Click here to register now!
We are thrilled to announce that we are taking the…
Weece Events is glad to invite you to attend the Global PHT Expo & Summit 2023 which is an International Conference & Exhibition on PHARMA, HEALTHCARE & TECHNOLOGY focusing on the Future of the Global Pharma & Healthcare Ecosystem in a digitally transforming world. The event is happening from 15-17th Feb 2023 at Hyatt Centric,…

